iwCLL 2023 | Key trials in CLL and designing a concept for treatment
Stephan Stilgenbauer
• 8 Oct 2023
Stephan Stilgenbauer, MD, Ulm University, Ulm, Germany, briefly comments on trials examining the efficacy of combinations of novel agents in treating patients with chronic lymphocytic leukemia (CLL). Dr Stilgenbauer believes that future trials should focus on designing a treatment concept for patients (several lines of treatment after a patient fails on experimental therapy) in order to improve overall survival. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
